Immune checkpoint inhibitors (ICIs) have been studied for utility in cancer since the 1990s and became Food and Drug Administration (FDA) approved in 2011 with the agent ipilimumab, an ICI targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [6-7]. Here, CTLA4 is linked to cancer.